893 - 1120 http://localhost:8080/xmlui/handle/123456789/9356 2026-04-09T00:48:09Z 2026-04-09T00:48:09Z http://localhost:8080/xmlui/handle/123456789/9449 2024-12-20T04:39:33Z 2023-10-01T00:00:00Z

Title: Clinical progression of asynchronous cutaneous lesions in a patient with locally acquired mpox infection Abstract: Abstract We present one of the earliest domestic mpox cases in Taiwan, highlighting the asynchronous and atypical progression of cutaneous lesions which could pose significant diagnostic challenges for clinicians.

2023-10-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9448 2024-12-20T04:37:10Z 2023-10-01T00:00:00Z

Title: A case of urogenital lymphogranuloma venereum in Taiwan

2023-10-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9447 2024-12-20T04:35:38Z 2023-08-01T00:00:00Z

Title: Herpes zoster aseptic meningitis and Ramsay Hunt syndrome in an immunocompetent young adult post mild COVID-19 e A coincidence?

2023-08-01T00:00:00Z Chen, Huei-Geng Chen, Jin-Shuen Chen, Yao-Shen Yin, Chun-Hao Chen, Hsiao-Ching Chiou, Yee-Hsuan http://localhost:8080/xmlui/handle/123456789/9446 2024-12-20T04:34:54Z 2023-10-01T00:00:00Z

Title: Comparison of mycophenolic acid with cyclophosphamide for the treatment of pediatric lupus nephritis: A retrospective study from a tertiary center hospital in Taiwan Authors: Chen, Huei-Geng; Chen, Jin-Shuen; Chen, Yao-Shen; Yin, Chun-Hao; Chen, Hsiao-Ching; Chiou, Yee-Hsuan Abstract: Abstract Background: This study aimed to compare the efficacy of mycophenolic acid (MPA) and cyclophosphamide (CYC) for treating pediatric lupus nephritis (pLN). Methods: Data on patients with pLN class III, IV, and V, diagnosed by renal biopsy, were collected from the Databank of Kaohsiung Veterans General Hospital between February 2005 and December 2020. The study included 31 pLN patients. Of these, 15 received MPA (MPA group) and 16 received CYC (CYC group). Systemic lupus erythematosus disease activity index score, laboratory findings, complete remission (CR), and partial remission (PR) were assessed at 6, 12, and 24 months. Results: In the MPA group, CR occurred in 7/15 (47%) patients at month 6 and in 11/15 (73%) at months 12 and 24. In the CYC group, CR was reached in 5/16 (31%) patients at month 6, in 8/16 (50%) at month 12, and in 9/16 (56%) at month 24. PR was seen in 3/15 (20%) patients in the MPA group and in 3/16 (19%) in the CYC group at month 24. The cumulative probability of CR and PR showed no statistically significant difference between the two groups. However, the estimated glomerular filtration rate (eGFR) improved significantly in the MPA group at months 6, 12 and 24 compared to that in the CYC group (p < 0.05). Conclusion: The efficacy of MPA is similar to that of CYC for pLN treatment, with MPA providing a significant improvement in eGFR after pLN induction therapy at months 6,12 and 24.

2023-10-01T00:00:00Z